The U.S. Food and Drug Administration has approved a drug called lenacapavir — a twice-a-year shot to protect against HIV ...

Audi Q3 arrives with bold design updates, improved efficiency, and a full range of engines designed for both performance and ...

Mercedes-AMG isn't the only business to find it tricky to chart the course of the performance car through ever-changing ...

Now, SRAM has trickled down that technology to its Force and Rival groupsets. Both groups gain 13 speed, wireless AXS ...

The "Traditional Chinese Medicine + Brain-Computer Interface" concept stock, BrainStorm Cell Therapeutics, which has attracted attention for several consecutive days, fell by 18.78% on Wednesday, with ...

KS Suspension adds the Rage Circuit to its lineup, lowering the cost of entry to wireless dropper posts. KS entered the wireless dropper market a little over a year and a half ago when it launched the ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Toshiba’s new automotive 2ch digital isolators are compliant with AEC-Q100 and realize stable operation with high common-mode ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...

During cell-to-cell spread, HIV-1 protease activity triggers CARD8 inflammasome activation and IL-1β release from macrophages, which may contribute to inflammation and chronic immune activation.